Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 KARDIA-2 Study Zilebesiran联合标准降压治疗对高血压控制不充分患者的降压作用...
Zilebesiran In Combination With A Standard-of-care Antihypertensive In Patients With Inadequately Controlled Hypertension - Primary Results From The Phase 2 KARDIA-2 Study Zilebesiran联合标准降压治疗对高血压控制不充分患者的降压作用 (KARDIA-2 试验) Akshay S. Desai教授公布KARDIA-2研究结果(罗江滢 摄自...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 5, 2024--Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development f...
The study found that Kardia 12L enabled rapid acquisition of resting ECG information, and concluded "this approach has significant implications for rapid ECG diagnosis in clinical practice." The poster can be accessedhere. Additional Features
In the Phase 2 KARDIA-1 study, single subcutaneous (SC) doses of zilebesiran monotherapy significantly reduced 24-hr mean ambulatory and office systolic blood pressure (SBP) from baseline to Months 3 and 6 versus placebo. The objective of KARDIA-2, a Phase 2 randomized, double-blind, ...
Design, Setting, and ParticipantsThis phase 2, randomized, double-blind, dose-ranging study of zilebesiran vs placebo was performed at 78 sites across 4 countries. Screening initiation occurred in July 2021 and the last patient visit of the 6-month study occurred in June 2023. Adults with mil...
In the phase 2 KARDIA-1 (NCT04936035) study, a single dose of zilebesiran monotherapy significantly reduced 24-hr mean ambulatory and office systolic blood pressure (SBP) from baseline to 3 and 6 months versus placebo in patients with mild to moderate hypertension. KARDIA-3, a phase 2 ...
A Phenomenological Study by Dr. Bill McFeature Read More HeartPath Practitioner A Practitioner’s Guide – The Healing Journey through the Life Narrative into the Heart of the Divine by Cinthia McFeature, Ph.D. & Bill McFeature, Ph.D. Read More {...
In den letzten Jahren finden strukturelle kardiale Interventionen zunehmend Anwendung in der klinischen Routine. Trotz der raschen Einführung und Weit
Apple Watch Vs Kardia to Monitor Afib From Home: A Case Study — The Skeptical Cardiologist weighs the usefulness of the two ECG devices The Skeptical Cardiologist received an email last week from a patient with paroxysmal atrial fibrillation (Afib) saying she was having an episode, documented ...